Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Bendamustine
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Aspirin
Drug: Prophylaxis
Drug: Antibiotic
Other: Biweekly Follow Up
Other: Cyclical Follow Up
Other: Restaging
Other: Post-Treatment Follow Up

First Posted Date: 2010-01-05

Last Posted Date: 2017-07-31

Lead Sponsor: Robert Redner, MD

Target Recruit Count: 29

Registration Number: NCT01042704

Locations: 🇺🇸
UPMC Cancer Centers - Arnold Palmer at Mountain View, Greensburg, Pennsylvania, United States
🇺🇸
UPMC Cancer Centers - Arnold Palmer at Oakbrook, Greensburg, Pennsylvania, United States
🇺🇸
Hematology/Oncology - Private Practice, McKeesport, Pennsylvania, United States

and more 19 locations

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2009-12-10

Last Posted Date: 2016-08-19

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 55

Registration Number: NCT01029730

Locations: 🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸
Hematology Oncology of the North Shore, Skokie, Illinois, United States
🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States

and more 17 locations

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

Early Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2009-12-01

Last Posted Date: 2017-01-10

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 17

Registration Number: NCT01022021

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Phase 3

Completed

Conditions: Marginal Zone Lymphomas
Non-Hodgkin Lymphomas
Follicular Lymphomas
Immunocytomas
Lymphocytic Lymphomas

Interventions: Drug: Standard chemotherapy CHOP + Ritiximab
Drug: Bendamustine

First Posted Date: 2009-10-07

Last Posted Date: 2024-08-22

Lead Sponsor: University of Giessen

Target Recruit Count: 549

Registration Number: NCT00991211

Locations: 🇩🇪
StiL Head Office; Justus-Liebig-University, Giessen, Germany

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bendamustine hydrochloride
Drug: lenalidomide

First Posted Date: 2009-10-01

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 49

Registration Number: NCT00987493

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Stadtspital Triemli, Zürich, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 13 locations

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: bendamustine hydrochloride

First Posted Date: 2009-09-25

Last Posted Date: 2014-03-12

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT00984542

Locations: 🇺🇸
Hardin Memorial Hosptial, Elizabethtown, Kentucky, United States
🇺🇸
Jackson-Madison County Hospital, Jackson, Tennessee, United States
🇺🇸
Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States

and more 3 locations

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab
Drug: Lenalidomide

First Posted Date: 2009-09-10

Last Posted Date: 2019-12-02

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 34

Registration Number: NCT00974233

Locations: 🇺🇸
Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States
🇺🇸
Gundersen Clinic, La Crosse, Wisconsin, United States
🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

and more 7 locations

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Phase 2

Completed

Conditions: T-cell Lymphoma

Interventions: Drug: Bendamustine

First Posted Date: 2009-08-17

Last Posted Date: 2013-02-12

Lead Sponsor: French Innovative Leukemia Organisation

Target Recruit Count: 45

Registration Number: NCT00959686

Locations: 🇫🇷
Dr Gandhi DAMAJ, Amiens, France

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Bendamustine
Drug: Alemtuzumab

First Posted Date: 2009-08-04

Last Posted Date: 2022-03-03

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 20

Registration Number: NCT00951457

Locations: 🇦🇹
Krankenhaus der Stadt Linz, Linz, Austria
🇦🇹
Universitaetsklinik f. Innere Medizin III, Salzburg, Austria
🇦🇹
A.ö. Landeskrankenhaus Leoben, Leoben, Austria

and more 4 locations

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1

Terminated

Conditions: Recurrent Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Small Lymphocytic Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Biological: Alemtuzumab

First Posted Date: 2009-07-28

Last Posted Date: 2013-08-22

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT00947388

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy